2. Academic Validation
  3. Development of 2,2-dimethylchromanol cysteinyl LT1 receptor antagonists

Development of 2,2-dimethylchromanol cysteinyl LT1 receptor antagonists

  • Bioorg Med Chem Lett. 1998 Dec 15;8(24):3577-82. doi: 10.1016/s0960-894x(98)00654-4.
R J Chambers 1,  G W Antognoli,  J B Cheng,  A V Kuperman,  T C Liston,  A Marfat,  B S Owens,  J S Pillar,  J T Shirley,  J W Watson
Affiliations

Affiliation

  • 1 Central Research Division, Pfizer Inc., Groton, CT 06340, USA.
PMID: 9934474 DOI: 10.1016/s0960-894x(98)00654-4
Abstract

A new series of cysLT1 receptor antagonists represented by CP-288,886 (7) and CP-265,298 (8) were developed which are equipotent to clinical cysLT1 receptor antagonists Zafirlukast (1) and Pranlukast (2).

Figures
Products